PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.58%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-14.34%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-20.40%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-19.61%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-20.61%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.76%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.74%
Negative OCF growth while Healthcare median is -10.20%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-26.42%
Negative FCF growth while Healthcare median is -6.69%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-91846.40%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-21838.35%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
2.60%
3Y OCF/share growth of 2.60% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-1109485.80%
Negative 10Y net income/share CAGR vs. Healthcare median of 8.02%. Seth Klarman might see a fundamental problem if peers maintain growth.
-20425.82%
Negative 5Y CAGR while Healthcare median is 0.11%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
78.21%
3Y net income/share CAGR > 1.5x Healthcare median of 4.15%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
41985.76%
Equity/share CAGR of 41985.76% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
3459.24%
5Y equity/share CAGR > 1.5x Healthcare median of 5.65%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
143.15%
3Y equity/share CAGR > 1.5x Healthcare median of 1.54%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-29.04%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth of 15.43% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
12.93%
SG&A growth of 12.93% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.